{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:42:36Z","timestamp":1785526956449,"version":"3.56.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-54494-0","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T09:46:51Z","timestamp":1779529611000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of JAK-inhibition on pain and biphasic P2X7R expression on CD4+ T cells in experimental arthritis"],"prefix":"10.1038","volume":"16","author":[{"given":"J\u00e9r\u00f4me","family":"Biton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxane","family":"Herv\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Breckler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Lemeiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Decker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Sigaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Assier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Semerano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha","family":"Bessis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christophe","family":"Boissier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Rivi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"key":"54494_CR1","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3899\/jrheum.200367","volume":"48","author":"KB Almutairi","year":"2021","unstructured":"Almutairi, K. B., Nossent, J. C., Preen, D. B., Keen, H. I. & Inderjeeth, C. A. The prevalence of rheumatoid arthritis: A systematic review of population-based studies. J. Rheumatol. 48, 669\u2013676 (2021).","journal-title":"J. Rheumatol."},{"key":"54494_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann. Rheum. Dis. 82, 3\u201318 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"54494_CR3","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1080\/13543784.2016.1249565","volume":"25","author":"L Semerano","year":"2016","unstructured":"Semerano, L., Decker, P., Clavel, G. & Boissier, M. C. Developments with investigational Janus kinase inhibitors for rheumatoid arthritis. Expert Opin. Investig. Drugs. 25, 1355\u20131359 (2016).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"54494_CR4","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s11926-012-0300-4","volume":"15","author":"YC Lee","year":"2013","unstructured":"Lee, Y. C. Effect and treatment of chronic pain in inflammatory arthritis. Curr. Rheumatol. Rep. 15, 300 (2013).","journal-title":"Curr. Rheumatol. Rep."},{"key":"54494_CR5","doi-asserted-by":"publisher","first-page":"105624","DOI":"10.1016\/j.jbspin.2023.105624","volume":"91","author":"B G\u00e9rard","year":"2024","unstructured":"G\u00e9rard, B., Bailly, F. & Trouvin, A. P. How to treat chronic pain in rheumatic and musculoskeletal diseases (RMDs) - A pharmacological review. Joint Bone Spine. 91, 105624 (2024).","journal-title":"Joint Bone Spine"},{"key":"54494_CR6","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nrrheum.2014.64","volume":"10","author":"DA Walsh","year":"2014","unstructured":"Walsh, D. A. & McWilliams, D. F. Mechanisms, impact and management of pain in rheumatoid arthritis. Nat. Rev. Rheumatol. 10, 581\u2013592 (2014).","journal-title":"Nat. Rev. Rheumatol."},{"issue":"Suppl 1","key":"54494_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1365-2982.2008.01110.x","volume":"20","author":"N Vergnolle","year":"2008","unstructured":"Vergnolle, N. Postinflammatory visceral sensitivity and pain mechanisms. Neurogastroenterol Motil. 20 (Suppl 1), 73\u201380 (2008).","journal-title":"Neurogastroenterol Motil."},{"key":"54494_CR8","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12974-016-0607-6","volume":"13","author":"YQ Zhou","year":"2016","unstructured":"Zhou, Y. Q. et al. Interleukin-6: an emerging regulator of pathological pain. J. Neuroinflammation. 13, 141 (2016).","journal-title":"J. Neuroinflammation"},{"key":"54494_CR9","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1136\/annrheumdis-2017-211259","volume":"76","author":"EC Keystone","year":"2017","unstructured":"Keystone, E. C. et al. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. Ann. Rheum. Dis. 76, 1853\u20131861 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"54494_CR10","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.semarthrit.2020.10.008","volume":"51","author":"LS Simon","year":"2021","unstructured":"Simon, L. S. et al. The Jak\/STAT pathway: A focus on pain in rheumatoid arthritis. Semin Arthritis Rheum. 51, 278\u2013284 (2021).","journal-title":"Semin Arthritis Rheum."},{"key":"54494_CR11","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/acr.23004","volume":"69","author":"V Strand","year":"2017","unstructured":"Strand, V. et al. Tofacitinib in combination with conventional disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: Patient-reported outcomes from a phase III randomized controlled trial. Arthritis Care Res. 69, 592\u2013598 (2017).","journal-title":"Arthritis Care Res."},{"key":"54494_CR12","doi-asserted-by":"publisher","first-page":"668","DOI":"10.55563\/clinexprheumatol\/e7ayu8","volume":"39","author":"N Crispino","year":"2021","unstructured":"Crispino, N. & Ciccia, F. JAK\/STAT pathway and nociceptive cytokine signalling in rheumatoid arthritis and psoriatic arthritis. Clin. Exp. Rheumatol. 39, 668\u2013675 (2021).","journal-title":"Clin. Exp. Rheumatol."},{"key":"54494_CR13","doi-asserted-by":"publisher","first-page":"831","DOI":"10.3390\/jcm8060831","volume":"8","author":"PC Taylor","year":"2019","unstructured":"Taylor, P. C. et al. Achieving pain control in rheumatoid arthritis with Baricitinib or adalimumab plus methotrexate: Results from the RA-BEAM trial. J Clin. Med. 8, 831 (2019).","journal-title":"J Clin. Med"},{"key":"54494_CR14","doi-asserted-by":"publisher","first-page":"e001994","DOI":"10.1136\/rmdopen-2021-001994","volume":"8","author":"PC Taylor","year":"2022","unstructured":"Taylor, P. C. et al. Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy. RMD Open. 8, e001994 (2022).","journal-title":"RMD Open."},{"key":"54494_CR15","doi-asserted-by":"publisher","first-page":"e002068","DOI":"10.1136\/rmdopen-2021-002068","volume":"8","author":"S Pazmino","year":"2022","unstructured":"Pazmino, S., Verschueren, P. & Westhovens, R. JAK inhibition and the holy grail for pain control in early RA. RMD Open. 8, e002068 (2022).","journal-title":"RMD Open."},{"key":"54494_CR16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13075-024-03354-1","volume":"26","author":"K Makabe","year":"2024","unstructured":"Makabe, K. et al. Baricitinib ameliorates inflammatory and neuropathic pain in collagen antibody-induced arthritis mice by modulating the IL-6\/JAK\/STAT3 pathway and CSF-1 expression in dorsal root ganglion neurons. Arthritis Res. Ther. 26, 121 (2024).","journal-title":"Arthritis Res. Ther."},{"key":"54494_CR17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.bcp.2017.12.021","volume":"151","author":"E Adinolfi","year":"2018","unstructured":"Adinolfi, E. et al. The P2X7 receptor: A main player in inflammation. Biochem. Pharmacol. 151, 234\u2013244 (2018).","journal-title":"Biochem. Pharmacol."},{"key":"54494_CR18","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1242\/jcs.112.3.297","volume":"112","author":"A Solini","year":"1999","unstructured":"Solini, A., Chiozzi, P., Morelli, A., Fellin, R. & Di Virgilio, F. Human primary fibroblasts in vitro express a purinergic P2X7 receptor coupled to ion fluxes, microvesicle formation and IL-6 release. J. Cell. Sci. 112, 297\u2013305 (1999).","journal-title":"J. Cell. Sci."},{"key":"54494_CR19","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.bbi.2007.08.007","volume":"22","author":"R Mingam","year":"2008","unstructured":"Mingam, R. et al. In vitro and in vivo evidence for a role of the P2X7 receptor in the release of IL-1 beta in the murine brain. Brain Behav. Immun. 22, 234\u2013244 (2008).","journal-title":"Brain Behav. Immun"},{"key":"54494_CR20","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1182\/blood-2005-06-031377","volume":"109","author":"C Pizzirani","year":"2007","unstructured":"Pizzirani, C. et al. Stimulation of P2 receptors causes release of IL-1beta-loaded microvesicles from human dendritic cells. Blood 109, 3856\u20133864 (2007).","journal-title":"Blood"},{"key":"54494_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.neulet.2011.08.058","volume":"504","author":"K Kobayashi","year":"2011","unstructured":"Kobayashi, K., Takahashi, E., Miyagawa, Y., Yamanaka, H. & Noguchi, K. Induction of the P2X7 receptor in spinal microglia in a neuropathic pain model. Neurosci. Lett. 504, 57\u201361 (2011).","journal-title":"Neurosci. Lett."},{"key":"54494_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.immuni.2017.06.020","volume":"47","author":"F Di Virgilio","year":"2017","unstructured":"Di Virgilio, F., Dal Ben, D., Sarti, A. C., Giuliani, A. L. & Falzoni, S. The P2X7 receptor in infection and inflammation. Immunity 47, 15\u201331 (2017).","journal-title":"Immunity"},{"key":"54494_CR23","first-page":"2951","volume":"26","author":"M Barber\u00e0-Cremades","year":"2012","unstructured":"Barber\u00e0-Cremades, M. et al. P2X7 receptor-stimulation causes fever via PGE2 and IL-1\u03b2 release. FASEB J. Off Publ Fed. Am Soc. Exp. Biol juill. 26, 2951\u20132962 (2012).","journal-title":"FASEB J. Off Publ Fed. Am Soc. Exp. Biol juill"},{"key":"54494_CR24","first-page":"878","volume":"32","author":"IB McInnes","year":"2014","unstructured":"McInnes, I. B., Cruwys, S., Bowers, K. & Braddock, M. Targeting the P2X7 receptor in rheumatoid arthritis: Biological rationale for P2X7 antagonism. Clin. Exp. Rheumatol. 32, 878\u2013882 (2014).","journal-title":"Clin. Exp. Rheumatol."},{"key":"54494_CR25","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1002\/art.10678","volume":"46","author":"G Dell\u2019Antonio","year":"2002","unstructured":"Dell\u2019Antonio, G., Quattrini, A., Cin, E. D., Fulgenzi, A. & Ferrero, M. E. Relief of inflammatory pain in rats by local use of the selective P2X7 ATP receptor inhibitor, oxidized ATP. Arthritis Rheum. 46, 3378\u20133385 (2002).","journal-title":"Arthritis Rheum."},{"key":"54494_CR26","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s13075-019-2047-z","volume":"21","author":"AL Mausset-Bonnefont","year":"2019","unstructured":"Mausset-Bonnefont, A. L. et al. Arthritis sensory and motor scale: Predicting functional deficits from the clinical score in collagen-induced arthritis. Arthritis Res. Ther. 21, 264 (2019).","journal-title":"Arthritis Res. Ther."},{"key":"54494_CR27","first-page":"41","volume":"64","author":"A Tanimoto","year":"2015","unstructured":"Tanimoto, A. et al. Pharmacological properties of JTE-052: A novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. Inflamm. Res. Off J. Eur. Histamine Res. Soc. Al. 64, 41\u201351 (2015).","journal-title":"Inflamm. Res. Off J. Eur. Histamine Res. Soc. Al"},{"key":"54494_CR28","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ard.2025.01.005","volume":"84","author":"N Simon","year":"2025","unstructured":"Simon, N. et al. Characterisation of the antinociceptive effect of baricitinib in the collagen antibody-induced arthritis mouse model. Ann. Rheum. Dis. 84, 421\u2013434 (2025).","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"54494_CR29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.immuni.2017.06.020","volume":"18","author":"F Di Virgilio","year":"2017","unstructured":"Di Virgilio, F. et al. The P2X7 receptor in infection and inflammation. Immunity 18 (1), 15\u201331 (2017).","journal-title":"Immunity"},{"issue":"5","key":"54494_CR30","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3390\/pharmaceutics14051001","volume":"6","author":"AM Shawky","year":"2022","unstructured":"Shawky, A. M. et al. A comprehensive overview of globally approved JAK inhibitors. Pharmaceutics 6 (5), 1001 (2022).","journal-title":"Pharmaceutics"},{"key":"54494_CR31","doi-asserted-by":"publisher","first-page":"35804","DOI":"10.1038\/srep35804","volume":"6","author":"ZD Fan","year":"2016","unstructured":"Fan, Z. D. et al. Involvement of P2X7 receptor signaling on regulating the differentiation of Th17 cells and type II collagen-induced arthritis in mice. Sci. Rep. 6, 35804 (2016).","journal-title":"Sci. Rep."},{"key":"54494_CR32","first-page":"1752","volume":"205","author":"M Li","year":"2020","unstructured":"Li, M. et al. The expression of P2X7 receptor on Th1, Th17, and regulatory T cells in patients with systemic lupus erythematosus or rheumatoid arthritis and its correlations with active disease. J. Immunol. Baltim. Md. 1950. 205, 1752\u20131762 (2020).","journal-title":"J. Immunol. Baltim. Md. 1950"},{"key":"54494_CR33","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/art.23152","volume":"58","author":"LAB Joosten","year":"2008","unstructured":"Joosten, L. A. B. et al. T cell dependence of chronic destructive murine arthritis induced by repeated local activation of Toll-like receptor-driven pathways: Crucial role of both interleukin-1beta and interleukin-17. Arthritis Rheum. 58, 98\u2013108 (2008).","journal-title":"Arthritis Rheum."},{"key":"54494_CR34","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1002\/art.21342","volume":"52","author":"MI Koenders","year":"2005","unstructured":"Koenders, M. I. et al. Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis. Arthritis Rheum. 52, 3239\u20133247 (2005).","journal-title":"Arthritis Rheum."},{"issue":"10","key":"54494_CR35","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1136\/annrheumdis-2011-143578","volume":"71","author":"EC Keystone","year":"2012","unstructured":"Keystone, E. C. et al. Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann. Rheum. Dis. 71 (10), 1630\u20131635 (2012).","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"54494_CR36","doi-asserted-by":"publisher","first-page":"720","DOI":"10.3899\/jrheum.110874","volume":"39","author":"TC Stock","year":"2012","unstructured":"Stock, T. C. et al. Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J. Rheumatol. 39 (4), 720\u2013727 (2012).","journal-title":"J. Rheumatol."},{"key":"54494_CR37","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1172\/JCI98814","volume":"128","author":"GAM Sanchez","year":"2018","unstructured":"Sanchez, G. A. M. et al. JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J. Clin. Invest. 128, 3041\u20133052 (2018).","journal-title":"J. Clin. Invest."},{"key":"54494_CR38","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1002\/eji.1830250508","volume":"25","author":"MC Boissier","year":"1995","unstructured":"Boissier, M. C. et al. Biphasic effect of interferon-gamma in murine collagen-induced arthritis. Eur. J. Immunol. 25, 1184\u20131190 (1995).","journal-title":"Eur. J. Immunol."},{"key":"54494_CR39","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1752-8062.2008.00013.x","volume":"1","author":"DL Mann","year":"2008","unstructured":"Mann, D. L., Bozkurt, B., Torre-Amione, G., Soran, O. Z. & Sivasubramanian, N. Effect of the soluble TNF-antagonist etanercept on tumor necrosis factor bioactivity and stability. Clin. Transl Sci. 1, 142\u2013145 (2008).","journal-title":"Clin. Transl Sci."},{"key":"54494_CR40","doi-asserted-by":"publisher","first-page":"19442","DOI":"10.1073\/pnas.0604827103","volume":"103","author":"H Le Buanec","year":"2006","unstructured":"Le Buanec, H. et al. TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation. Proc. Natl. Acad. Sci. U S A. 103, 19442\u201319447 (2006).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"54494_CR41","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jneumeth.2015.08.010","volume":"255","author":"MJG Bradman","year":"2015","unstructured":"Bradman, M. J. G., Ferrini, F., Salio, C. & Merighi, A. Practical mechanical threshold estimation in rodents using von Frey hairs\/Semmes-Weinstein monofilaments: Towards a rational method. J. Neurosci. Methods. 255, 92\u2013103 (2015).","journal-title":"J. Neurosci. Methods"},{"key":"54494_CR42","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/0090-1229(88)90086-4","volume":"48","author":"MC Boissier","year":"1988","unstructured":"Boissier, M. C., Carlioz, A. & Fournier, C. Experimental autoimmune arthritis in mice. II. Early events in the elicitation of the autoimmune phenomenon induced by homologous type II collagen. Clin. Immunol. Immunopathol. 48, 225\u2013237 (1988).","journal-title":"Clin. Immunol. Immunopathol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54494-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54494-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54494-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:07:15Z","timestamp":1785521235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54494-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["54494"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-54494-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"5 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Eli Lilly provided the drug and funding for the study. Eli Lilly was not involved in study design, data collection, data analysis, data interpretation and writing of the manuscript. There was no approval of the manuscript by Eli Lilly before submission. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The local Ethics Committee on Animal Care and Experimentation (#25279) approved all experimental procedures related to animals. All in vivo experiments were conducted in accordance with the recommendations for animal experimentation issued by the Institutes of Laboratory Animal Resources committee and the ARRIVE guidelines.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"23607"}}